Competition

USDOJ 2017 UPDATE OF THE ANTITRUST GUIDELINES FOR THE LICENSING OF INTELLECTUAL PROPERTY STANDARD SETTING AND COMPETITION November 8, 2012 COMPETITION, INNOVATION AND INTELLECTUAL PROPERTY, April 26, 2012 CHAPTER 6 : COMPETITIVE ISSUES REGARDING PRACTICES THAT EXTEND THE MARKET POWER… Continue Reading

KEI asks FTC to investigate Shire decision to abandon efforts to compete in US market for Fabry’s disease treatments

July 15, 2014

Knowledge Ecology International (KEI) asks the FTC to investigate Shire decision to abandon efforts to compete in US market for Fabry’s disease treatments. Letter to FTC provides evidence of possible conspiracy to segment markets, involving licensing of an NIH funded invention for use in Europe, in return for abandoning efforts to enter US market.

For More Information:

James Love, Knowledge Ecology International
Email: james.love@keionline.org
Tel +1.202.332.2670
Cell +1.202.361.3040

Continue Reading

Resurrecting the Ghost of Høsbjør Past: Global Fund seeks to establish global framework on tiered pricing enforced by WTO rules

Informed sources have revealed that Mark Dybul, Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, is the brains behind an initiative to create global framework for the tiered pricing or in the Global Fund’s own words, “Equitable Access to Essential Medicines and Vaccines: Developing a Framework for Success”, enforced by the rules of the World Trade Organization. KEI has obtained this internal concept note prepared by the Global Fund which we understand is a work in progress.

Continue Reading

1

KEI Statement on India’s granting of compulsory license to patents on cancer drug sorafenib (NATCO Vs. BAYER)

The India Controller General Controller General of Patents, Designs & Trade Marks has just (March 12, 2012) issued an order granting a compulsory license to patents on the cancer drug sorafenib/Nexavar, in the matter of NATCO Vs. BAYER. A copy of the decision is attached below.

Continue Reading

John LaMattian, former head of Pfizer R&D, says industry mergers have harmed R&D efforts

John L. LaMattina, the former President of Pfizer Global Research and Development, has just published an article in Nature that looks at the impact of drug company mergers and increased industry concentration on R&D. Among his conclusions: the “impact on the R&D of the organizations involved has been devastating.”

http://www.nature.com/nrd/journal/v10/n8/full/nrd3514.html

COMMENT

NATURE REVIEWS | DRUG DISCOVERY VOLUME 10 | AUGUST 2011 | 559

The impact of mergers on pharmaceutical R&D

Continue Reading

59 U.S. Senators write the EU to support Oracle acquisition of MYSQL

On the 24th of November, 59 U.S. Senators wrote the European Union, asking that the Oracle/Sun merger be allowed, without addressing the anticompetitive aspects of the Oracle acquisition of MySQL. The letter reflects the enormous influence wielded by Oracle, a company that generates enormous fees licensing database software to the federal government. Continue Reading

KEI, Richard Stallman, ORG, letter to European Commission opposing Oracle acquisition of MySQL assets from Sun

KEI, Richard Stallman, ORG, letter to European Commission opposing Oracle acquisition of MySQL assets from Sun The following is a letter that KEI, Richard Stallman and ORG have sent to the European Commission, asking the European Commission to prevent Oracle… Continue Reading